News

VPM at the OPTIMMUNIZE 2022 Meeting

VPM at the OPTIMMUNIZE 2022 Meeting VPM was invited guest speaker at the OPTIMMUNIZE 2022 which was held as webinar on April 21st. Watch the video here!
more

Prime update: visit to the East African clinical sites

We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.

more

Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology

The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.

more

priMe update: visit of the South African clinical sites

We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we’ll meet more often in person again.

more

Updates on priMe

The priMe organizational team (VPM, SIIPL, DiagnoSearch, IAVI) met last week at SIIPL in Pune, India to discuss the status of the project and how to streamline certain procedures to achieve the milestones and bring the trial to success.

more